# Forensic Dossier: Study Forensics: Rapamycin for human longevity — promise vs proof

**Run ID:** `full27_study-forensics-031_Claude_Haiku_e24172`  
**Task:** study-forensics-031 | study_forensics | hard | study_forensics  
**Timestamp:** 2026-04-08T17:06:13.942104+00:00  
**Task Family:** solid  
**Trap Type:** overflagging_cautious_early_data  
**Ambiguity:** medium  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **73.9/100** (margin: 0.0)
**Failure modes:** named_not_explained, unsupported_conclusion, unsupported_intermediate_step
**Forensic flags:** 5
**Consistency findings:** 7
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 30.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 3.9/6 | 6.0/6 | 6.4/8 | 8.0/8 | 1.5/10 | 8.5/10 | **73.9/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `solid` [+] (gold: `solid`)
**Finding Recall:** 100%
**Matched Findings:** evidence_matches_claim, cautious_scope_control
**Extra Findings:** none_or_minor, conclusion_exceeds_results, decorative_uncertainty, mechanism_not_demonstrated, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct but brittle reasoning
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "solid"


## Forensic Flags

### Claude Haiku

- **[MODERATE]** `weak_mechanism`: Correct answer but weak mechanism explanation — answer may not generalize
  - `final_answer`: "solid"
- **[MAJOR]** `unsupported_leap`: Correct answer with weak support chain — final answer may be an unsupported leap
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "solid"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"
- **[MINOR]** `study_forensics_overflagging`: Agent raised extra findings in solid case: none_or_minor, conclusion_exceeds_results, decorative_uncertainty, mechanism_not_demonstrated, correlation_as_causation


## Evidence Map

### Claude Haiku

**Correctness:** 30.0/30
  - (+) `final_answer`: "solid"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 0.0/8
  - (-) `final_answer`: "solid"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[0]`: "1. EVIDENCE TIER IDENTIFICATION: The strongest evidence presented is from animal models (mice showing 10-25% lifespan ex"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[1]`: "The human trial described is indeed the 'first well-designed' trial for this indication."
    _Most substantive assumption_
  - Note: 4/4 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[1]`: "The specific design of the human trial (sample size, duration, population) — the text does not provide these details, so"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - Note: 4 uncertainties (4 substantive)
  - Note: Confidence 0.92

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[0]`: "Could classify as mechanism_vs_evidence if interpreting the mention of off-label use as implicit endorsement — but the t"
    _Most substantive alternative hypothesis_
  - Note: 3 alternative hypotheses considered
  - Note: 3/3 include rejection reasoning

**Self Monitoring Quality:** 6.4/8
  - (+) `self_check[3]`: "Did I assume the human trial was poorly designed? No — the text says it was well-designed; it simply had a negative prim"
    _Most substantive self-verification step_
  - Note: 6 self-check items
  - Note: Self-check quality: 0 deep, 6 arithmetic, 0 fluff

**Mechanism Quality:** 1.5/10
  - Note: Names concept but does not describe mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.72, 650 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 3 full / 3


## Failure Analysis

### Claude Haiku

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "solid"
  - _Impacts: support_strength_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Names the phenomenon but does not explain the causal mechanism
  - `final_answer`: "solid"
  - _Impacts: mechanism_quality_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Named concept(s) ['effect'] but mechanism not described
  - _Impacts: mechanism_quality, insight_depth_
- **Unsupported Intermediate Step** `[MEDIUM CONFIDENCE]`: No reasoning step is load-bearing — final answer lacks traceable derivation
  - `final_answer`: "solid"
  - _Impacts: support_strength, structural_reasoning_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/9 content words)
  - `key_claims[0]`: "Mouse lifespan extension (10-25%, replicated) is presented as established animal evidence."
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/11 content words)
  - `key_claims[1]`: "Human trial failed its primary endpoint (abdominal fat reduction) and showed only modest secondary e"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/6 content words)
  - `key_claims[2]`: "No human trial tested biological aging directly."
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/8 content words)
  - `key_claims[3]`: "Expert consensus: no clinical evidence supports aging benefits in humans."
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 5 has low overlap with final answer (0/7 content words)
  - `key_claims[4]`: "Off-label use carries risks, especially for immunocompromised or cancer patients."
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 6 has low overlap with final answer (0/9 content words)
  - `key_claims[5]`: "The text does NOT claim rapamycin slows aging in humans; it explicitly denies this claim has evidenc"
- **[WARN]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Phenomenon is named but causal mechanism is not explained
  - `final_answer`: "solid"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 14435ms

**Final Answer:** solid

**Confidence:** 0.92

**Assumptions:**
- The text accurately represents the mouse lifespan studies as replicated and reliable.
- The human trial described is indeed the 'first well-designed' trial for this indication.
- The primary endpoint (abdominal fat reduction) is a reasonable proxy for aging benefit.
- The text is reporting on actual published findings, not speculative claims.

**Reasoning Steps:**
1. 1. EVIDENCE TIER IDENTIFICATION: The strongest evidence presented is from animal models (mice showing 10-25% lifespan extension, replicated). The human evidence is limited: one well-designed trial with a failed primary endpoint and modest secondary outcomes, no aging biomarkers tested.
2. 2. CONCLUSION TIER IDENTIFICATION: The text discusses off-label human use by enthusiasts and expert cautions about human aging effects. The conclusion tier is human_therapeutic (whether rapamycin slows aging in people).
3. 3. BRIDGE GAP ANALYSIS: There is a substantial gap between animal lifespan data and human aging outcomes. The text explicitly acknowledges this: 'no clinical evidence yet shows rapamycin slows aging in people.'
4. 4. HEDGE QUALITY CHECK: The text does NOT use decorative uncertainty. Instead, it clearly states the evidence gap: the human trial 'did not test whether the drug slows biological aging' and experts 'caution that no clinical evidence yet shows' the effect. This is honest acknowledgment, not hedging that masks a claim.
5. 5. CLAIM STRUCTURE: The text separates three distinct claims: (a) mouse data (strong, replicated), (b) human trial results (negative primary endpoint, modest secondary), (c) expert consensus (no human aging evidence). None of these claims exceed their evidence tier.
6. 6. OFF-LABEL USE CONTEXT: The text notes enthusiasts take it off-label but immediately contextualizes this as unsupported by clinical evidence and risky. This is not endorsement; it is factual reporting of behavior with appropriate caution.
7. 7. RISK ACKNOWLEDGMENT: The text mentions specific risks (active cancer), showing awareness of confounders and contraindications.

**Key Claims:**
- Mouse lifespan extension (10-25%, replicated) is presented as established animal evidence.
- Human trial failed its primary endpoint (abdominal fat reduction) and showed only modest secondary effects.
- No human trial tested biological aging directly.
- Expert consensus: no clinical evidence supports aging benefits in humans.
- Off-label use carries risks, especially for immunocompromised or cancer patients.
- The text does NOT claim rapamycin slows aging in humans; it explicitly denies this claim has evidence.

**Alternative Hypotheses:**
- Could classify as mechanism_vs_evidence if interpreting the mention of off-label use as implicit endorsement — but the text explicitly cautions against it and denies clinical support.
- Could classify as overclaim if the text were asserting that rapamycin *does* slow aging in humans — but it explicitly denies this.
- Could classify as correlation_vs_causation if the text were claiming the mouse lifespan extension proves a causal mechanism in humans — but it does not make this leap.

**Uncertainties:**
- Whether the human trial is truly the 'first well-designed' trial or if other trials exist but are not mentioned.
- The specific design of the human trial (sample size, duration, population) — the text does not provide these details, so I cannot verify the claim of 'well-designed.'
- Whether the modest lean muscle increase in women is clinically meaningful or just statistically significant.
- The current state of expert consensus — the text cites 'experts caution' but does not specify which experts or provide citations.

**Self-Verification:**
- Did I confuse 'the text mentions off-label use' with 'the text endorses off-label use'? No — the text clearly cautions against it.
- Did I flag the animal-to-human gap as a problem with the text? No — the text itself acknowledges this gap explicitly.
- Did I mistake cautious language for decorative uncertainty? No — the caution here is substantive and accurate.
- Did I assume the human trial was poorly designed? No — the text says it was well-designed; it simply had a negative primary endpoint, which is honest reporting.
- Is there an overclaim hiding in the text? No — the text does not claim human benefit; it reports failure of the primary endpoint.
- Did I miss a correlation-vs-causation error? No — the text does not claim the mouse data proves causation in humans.

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 6.4/8 `########..`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 1.5/10 `#.........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **73.9/100**.

**Best per dimension:**
- Correctness: Claude Haiku (30.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (6.0/6)
- Self Monitoring Quality: Claude Haiku (6.4/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (1.5/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 14.4s | 73.9/100 | 5.1 |

Failure modes observed: named_not_explained, unsupported_conclusion, unsupported_intermediate_step.
